Syngene International Limited (SYNGENE) - Net Assets

Latest as of September 2025: Rs47.35 Billion INR ≈ $512.06 Million USD

Based on the latest financial reports, Syngene International Limited (SYNGENE) has net assets worth Rs47.35 Billion INR (≈ $512.06 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs65.42 Billion ≈ $707.50 Million USD) and total liabilities (Rs18.07 Billion ≈ $195.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Syngene International Limited to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Rs47.35 Billion
% of Total Assets 72.38%
Annual Growth Rate 23.74%
5-Year Change 67.53%
10-Year Change 348.97%
Growth Volatility 15.67

Syngene International Limited - Net Assets Trend (2010–2025)

This chart illustrates how Syngene International Limited's net assets have evolved over time, based on quarterly financial data. Also explore Syngene International Limited assets under control for the complete picture of this company's asset base.

Annual Net Assets for Syngene International Limited (2010–2025)

The table below shows the annual net assets of Syngene International Limited from 2010 to 2025. For live valuation and market cap data, see SYNGENE stock market capitalisation.

Year Net Assets Change
2025-03-31 Rs47.27 Billion
≈ $511.19 Million
+11.02%
2024-03-31 Rs42.58 Billion
≈ $460.46 Million
+17.68%
2023-03-31 Rs36.18 Billion
≈ $391.27 Million
+9.72%
2022-03-31 Rs32.98 Billion
≈ $356.62 Million
+16.88%
2021-03-31 Rs28.21 Billion
≈ $305.12 Million
+29.67%
2020-03-31 Rs21.76 Billion
≈ $235.30 Million
+10.54%
2019-03-31 Rs19.68 Billion
≈ $212.87 Million
+14.42%
2018-03-31 Rs17.20 Billion
≈ $186.05 Million
+21.75%
2017-03-31 Rs14.13 Billion
≈ $152.82 Million
+34.22%
2016-03-31 Rs10.53 Billion
≈ $113.86 Million
+24.61%
2015-03-31 Rs8.45 Billion
≈ $91.37 Million
+28.15%
2014-03-31 Rs6.59 Billion
≈ $71.30 Million
+27.13%
2013-03-31 Rs5.19 Billion
≈ $56.08 Million
+74.73%
2012-03-31 Rs2.97 Billion
≈ $32.10 Million
+34.48%
2011-03-31 Rs2.21 Billion
≈ $23.87 Million
+14.06%
2010-03-31 Rs1.94 Billion
≈ $20.93 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Syngene International Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1987.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings Rs38.82 Billion 82.13%
Common Stock Rs4.03 Billion 8.52%
Other Comprehensive Income Rs2.04 Billion 4.31%
Other Components Rs2.38 Billion 5.04%
Total Equity Rs47.27 Billion 100.00%

Syngene International Limited Competitors by Market Cap

The table below lists competitors of Syngene International Limited ranked by their market capitalization.

Company Market Cap
SIRIUSPOINT LTD. DL-10
F:3XPA
$2.03 Billion
Nanjing Gaoke Co Ltd
SHG:600064
$2.03 Billion
Huizhou Speed Wireless Technology Co Ltd
SHE:300322
$2.03 Billion
Suzhou Shijia Science & Technology Inc
SHE:002796
$2.03 Billion
Sino Geophysical
SHE:300191
$2.03 Billion
Polaris Bay Group Co Ltd
SHG:600155
$2.03 Billion
Jiugui Liquor Co Ltd
SHE:000799
$2.03 Billion
Schiehallion Fund Ltd
LSE:MNTN
$2.03 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Syngene International Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 42,577,000,000 to 47,268,000,000, a change of 4,691,000,000 (11.0%).
  • Net income of 4,962,000,000 contributed positively to equity growth.
  • Dividend payments of 503,000,000 reduced retained earnings.
  • Share repurchases of 5,000,000 reduced equity.
  • New share issuances of 5,000,000 increased equity.
  • Other comprehensive income decreased equity by 43,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Rs4.96 Billion +10.5%
Dividends Paid Rs503.00 Million -1.06%
Share Repurchases Rs5.00 Million -0.01%
Share Issuances Rs5.00 Million +0.01%
Other Comprehensive Income Rs-43.00 Million -0.09%
Other Changes Rs275.00 Million +0.58%
Total Change Rs- 11.02%

Book Value vs Market Value Analysis

This analysis compares Syngene International Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.98x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 81.80x to 3.98x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-03-31 Rs5.72 Rs467.65 x
2011-03-31 Rs6.52 Rs467.65 x
2012-03-31 Rs8.76 Rs467.65 x
2013-03-31 Rs14.74 Rs467.65 x
2014-03-31 Rs16.75 Rs467.65 x
2015-03-31 Rs21.46 Rs467.65 x
2016-03-31 Rs26.65 Rs467.65 x
2017-03-31 Rs35.78 Rs467.65 x
2018-03-31 Rs43.45 Rs467.65 x
2019-03-31 Rs49.62 Rs467.65 x
2020-03-31 Rs54.65 Rs467.65 x
2021-03-31 Rs70.42 Rs467.65 x
2022-03-31 Rs81.84 Rs467.65 x
2023-03-31 Rs89.64 Rs467.65 x
2024-03-31 Rs105.92 Rs467.65 x
2025-03-31 Rs117.59 Rs467.65 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Syngene International Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.50%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 13.62%
  • • Asset Turnover: 0.54x
  • • Equity Multiplier: 1.44x
  • Recent ROE (10.50%) is below the historical average (17.33%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 15.71% 11.52% 0.52x 2.65x Rs110.50 Million
2011 12.32% 8.61% 0.63x 2.28x Rs51.30 Million
2012 23.92% 17.38% 0.70x 1.98x Rs413.20 Million
2013 19.69% 18.56% 0.76x 1.40x Rs502.40 Million
2014 26.54% 20.35% 0.72x 1.81x Rs1.09 Billion
2015 20.71% 20.35% 0.60x 1.68x Rs905.10 Million
2016 22.87% 21.75% 0.46x 2.27x Rs1.36 Billion
2017 20.33% 23.92% 0.43x 1.96x Rs1.46 Billion
2018 17.75% 21.46% 0.45x 1.85x Rs1.33 Billion
2019 16.85% 18.16% 0.49x 1.88x Rs1.35 Billion
2020 18.94% 20.48% 0.48x 1.91x Rs1.95 Billion
2021 14.35% 18.54% 0.45x 1.73x Rs1.23 Billion
2022 12.00% 15.20% 0.47x 1.69x Rs660.40 Million
2023 12.84% 14.54% 0.55x 1.61x Rs1.03 Billion
2024 11.98% 14.62% 0.57x 1.44x Rs842.30 Million
2025 10.50% 13.62% 0.54x 1.44x Rs235.20 Million

Industry Comparison

This section compares Syngene International Limited's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $4,775,438,672
  • Average return on equity (ROE) among peers: 13.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Syngene International Limited (SYNGENE) Rs47.35 Billion 15.71% 0.38x $2.03 Billion
Krsnaa Diagnostics Limited (KRSNAA) $-228.96 Million 0.00% 0.00x $206.54 Million
Dr. Lal Path Labs Ltd. (LALPATHLAB) $5.10 Billion 25.94% 0.23x $2.47 Billion
Metropolis Healthcare Limited (METROPOLIS) $13.35 Billion 10.86% 0.40x $267.10 Million
Thyrocare Technologies Limited (THYROCARE) $3.67 Billion 24.11% 0.28x $689.03 Million
Vijaya Diagnostic Centre Limited (VIJAYA) $5.47 Billion 15.48% 0.56x $1.26 Billion
Vimta Labs Limited (VIMTALABS) $1.31 Billion 2.03% 0.39x $220.67 Million

About Syngene International Limited

NSE:SYNGENE India Diagnostics & Research
Market Cap
$2.03 Billion
Rs187.86 Billion INR
Market Cap Rank
#6193 Global
#271 in India
Share Price
Rs467.65
Change (1 day)
+8.21%
52-Week Range
Rs389.90 - Rs722.05
All Time High
Rs947.80
About

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and anal… Read more